Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 30 (October 20), 2005: pp. 7654-7659
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.01.4340

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, J. Y.
Right arrow Articles by Kim, B.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, J. Y.
Right arrow Articles by Kim, B.-T.

Improved Detection of Second Primary Cancer Using Integrated [18F] Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Initial Tumor Staging

Joon Young Choi, Kyung Soo Lee, O. Jung Kwon, Young Mog Shim, Chung-Hwan Baek, Keunchil Park, Kyung-Han Lee, Byung-Tae Kim

From the Departments of Nuclear Medicine, Radiology, Medicine, Thoracic Surgery, and Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Address reprint requests to Byung-Tae Kim, MD, Department of Nuclear Medicine, Samsung Medical Center, 50 Ilwon-dong, Kangnam-ku 135-710 Seoul Republic of Korea; e-mail: btnm.kim{at}samsung.com

PURPOSE: This study evaluated prospectively the value of integrated whole-body positron emission tomography and computed tomography (PET/CT) using [18F] fluorodeoxyglucose (FDG) in detecting a second primary cancer at the time of the initial staging in comparison with a conventional staging work-up (CSW).

METHODS: The participants were 547 patients diagnosed with cancer who underwent FDG PET/CT imaging for the initial staging. An additional diagnostic evaluation was performed when there were abnormal findings indicative of a second primary cancer on either PET/CT or CSW considering the site and the biologic behavior of the alleged primary tumor.

RESULTS: A total of 27 second primary malignant tumors were identified in 26 of the 547 patients (4.8%). FDG PET/CT found 45 lesions indicative of a second primary cancer, of which 24 lesions were proved to be a second primary cancer, seven were clinically unexpected metastases, and 14 lesions were benign. Therefore, sensitivity and positive predictive value of FDG PET/CT in detecting a second primary cancer or an unexpected metastasis were 91% (31 of 34) and 69% (31 of 45), respectively. In contrast, CSW could not identify 16 second primary cancers and one metastatic lesion.

CONCLUSION: FDG PET/CT at the time of the initial staging is useful for screening a second primary cancer with a high sensitivity. An additional diagnostic work-up is essential when abnormal findings, which are indicative of a second primary cancer, are obtained on PET/CT images to rule out the presence of either a second primary cancer or an unexpected metastasis.

Presented in part at the Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, June 19-23, 2004.

Supported by Grant No. 02-PJ3-PG6-EV06-0002 from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
RadiologyHome page
C. A Yi, K. M. Shin, K. S. Lee, B.-T. Kim, H. Kim, O J. Kwon, J. Y. Choi, and M. J. Chung
Non-Small Cell Lung Cancer Staging: Efficacy Comparison of Integrated PET/CT versus 3.0-T Whole-Body MR Imaging
Radiology, August 1, 2008; 248(2): 632 - 642.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Y. Kim, J.-L. Roh, N.-K. Yeo, J. S. Kim, J. H. Lee, S.-H. Choi, and S. Y. Nam
Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer
Ann. Onc., October 1, 2007; 18(10): 1698 - 1703.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H.-S. Jeong, M. K. Chung, Y.-I. Son, J. Y. Choi, H. J. Kim, Y. H. Ko, and C.-H. Baek
Role of 18F-FDG PET/CT in Management of High-Grade Salivary Gland Malignancies
J. Nucl. Med., August 1, 2007; 48(8): 1237 - 1244.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W. De Wever, Y. Vankan, S. Stroobants, and J. Verschakelen
Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer
Eur. Respir. J., May 1, 2007; 29(5): 995 - 1002.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. Y. Choi, K. S. Lee, H.-J. Kim, Y. M. Shim, O. J. Kwon, K. Park, C.-H. Baek, J. H. Chung, K.-H. Lee, and B.-T. Kim
Focal Thyroid Lesions Incidentally Identified by Integrated 18F-FDG PET/CT: Clinical Significance and Improved Characterization
J. Nucl. Med., April 1, 2006; 47(4): 609 - 615.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online